Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma

Cancer

Volumn 107, Issue 6, 2006, Pages 1348-1354

  Rivera, Edgardo ^a,b   Meyers, Christina ^a   Groves, Morris ^a   Valero, Vicente ^a   Francis, Deborah ^a   Arun, Banu ^a   Broglio, Kristine ^a   Yin, Guosheng ^a   Hortobagyi, Gabriel N ^a   Buchholz, Thomas ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b NONE   (United States)

Author keywords

Breast neoplasms; Capecitabine; Neural metastases; Temozolomide

Indexed keywords

ANTIBIOTIC AGENT; ANTIEMETIC AGENT; CAPECITABINE; TEMOZOLOMIDE;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; BRAIN METASTASIS; BRAIN TUMOR; BREAST CARCINOMA; CEREBELLUM TUMOR; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITION; COHORT ANALYSIS; CONSTIPATION; DOSE CALCULATION; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; EVALUATION; FATIGUE; FEMALE; FEVER; HAND FOOT SYNDROME; HEADACHE; HISTOLOGY; HUMAN; INFECTION; MALE; MAXIMUM TOLERATED DOSE; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SEPSIS; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; BREAST NEOPLASMS; COHORT STUDIES; DACARBAZINE; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FATIGUE; FEMALE; HUMANS; MIDDLE AGED; NAUSEA; TREATMENT OUTCOME; VOMITING;

EID: 33749026073     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22127     Document Type: Article

References (24)

1. Hutter A, Schwetye K, Bierhals A, McKinstry R. Brain neoplasms: epidemiology, diagnosis, and prospects for cost-effective imaging. Neuroimaging Clin N Am. 2003;2:237-250.
2. Honig A, Rieger L, Sutterlin A, et al. Brain metastases in breast cancer - an in vitro study to evaluate new systemic chemotherapeutic options. Anticancer Res. 2005;25:1531-1537.
3. Kirsch DG, Loeffler JS. Brain metastases in patients with breast cancer: new horizons. Clin Breast Cancer. 2005;6:115-124.
4. Lin NU, Bellon JR, Winer EP. CNS metastases in breast cancer. J Clin Oncol. 2004;22:3608-3617.
5. Surma-aho O, Niemela M, Vilkki J, et al. Adverse long-term effects of brain radiotherapy in adult low-grade glioma patients. Neurology. 2001;56:1285-1290.
6. DeAngelis LM, Delattre JY, Posner JB. Radiation-induced dementia in patients cured of brain metastases. Neurology. 1989;39:789-796.
7. Fenner MH, Possinger K. Chemotherapy for breast cancer brain metastases. Onkologie. 2002;25:474-479.
8. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987-996.
9. Antonadou D, Paraskevaidis M, Sarris G, et al. Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases. J Clin Oncol. 2002;20:3644-3650.
10. Abrey LE, Olson JD, Raizer JJ, et al. A phase II trial of temozolomide for patients with recurrent or progressive brain metastases. J Neurooncol 2001;53:259-265.
11. Martinez-Cedillo J, Alvarado A, Lara F, et al. Temozolomide (TMZ) in metastatic breast cancer (BC) to central nervous system (CNS). Proc Am Soc Clin Oncol. 2003;22:88. Abstract.
12. Christodoulou C, Bafaloukos D, Kosmidis P, et al. Phase II study of temozolomide in heavily pretreated cancer patients with brain metastases. Ann Oncol. 2001;12:249-254.
13. Wang ML, Yung WK, Royce ME, Schomer DF, Theriault RL. Capecitabine for 5-fluorouracil-resistant brain metastases from breast cancer. Am J Clin Oncol. 2001;24:421-424.
14. Siegelmann-Danieli N, Stein M, Bar-Ziv J. Complete response of brain metastases originating in breast cancer to capecitabine therapy. Isr Med Assoc J. 2003;5:833-834.
15. Zubrod C, Scheiderman M, Frei E, et al. Appraisal of methods for the study of chemotherapy of cancer in man: comparative therapeutic trial of nitrogen mustard and thiophosphoamide. J Chron Dis. 1960;11:7-33.
16. Benedict RHB, Schretien D, Groninger L, et al. Hopkins verbal learning test-revised: normative data and analysis of inter-form and test-retest reliability. Clin Neuropsychol. 1998;12:43-55.
17. Benton AL, Hamsher KDS. Multilingual Aphasia Examination. 3rd edition. Iowa City, IA: AJA Association, 1989.
18. Wechsler D. Wechsler Adult Intelligence Scale III. 3rd ed. San Antonio, TX: Psychological Corporation, 1997.
19. Lezak MD. Neuropsychological Assessment, 3rd ed. New York: Oxford University Press, 1995.
20. Cella D, Nowinski CJ. Measuring quality of life in chronic illness: the functional assessment of chronic illness therapy measurement system. Arch Phys Med Rehabil. 2002;83:S10-S17.
21. Meyers CA, Smith JA, Bezjak A, et al. Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial. J Clin Oncol. 2004;22:157-165.
22. Boogerd W, Dalesio O, Bais EM, van der Sande JJ. Response of brain metastases from breast cancer to systemic chemotherapy. Cancer. 1992;69:972-980.
23. Trudeau ME, Eisenhauer E, Dent S, et al. Central nervous system (CNS) relapse following chemotherapy with docetaxel for metastatic breast cancer. Update of a study by the National Cancer Institute of Canada-Clinical Trials Group (NCIC-CTG). Proc Am Soc Clin Oncol. 1996;15:101. Abstract 68.
24. Siena S, Landonio G, Baietta E, et al. Multicenter phase II study of temozolomide therapy for brain metastasis in patients with malignant melanoma, breast cancer, and non-small lung cancer. Proc Am Soc Clin Oncol. 2003;22:102. Abstract.